Dr Reck meets with ecancertv at ESMO 2016 to discuss results from the KEYNOTE-024 trial which he believes recommend the use of PD1 antibody pembrolizumab as first-line therapy for patients with NSCLC whose tumours express high levels of PDL-1.

Video of the press conference in which he announced these findings is available here.

Dr Corey Langer discussed complimentary results from KEYNOTE-021, which found improved outcomes for NSCLC patients receiving firstline pembrolizumab and chemotherapy, with ecancer here.